25 research outputs found
Calidad de vida en los pacientes con psoriasis
La psoriasis en una enfermedad sistémica crónica que conlleva exacerbaciones y remisiones a lo largo de la vida del paciente .Sólo se conocía la artropatía psoriásica como otra entidad nosológica asociada a la psoriasis cutánea. Sin embargo, en la actualidad se conoce ampliamente otras enfermedades relacionadas, patologías orgánicas, como es la enfermedad cardiovascular englobando en ella a todos sus factores de riesgo, así como patologías de la esfera psíquica que con frecuencia se manifiestan en estos pacientes.
Estas patologías asociadas, ha cambiado de forma importante el abordaje que el dermatólogo debe hacer del paciente con psoriasis, llevando a cabo una visión integral desde el punto de vista orgánico del paciente, con la intención de obtener un diagnóstico temprano de las posibles comorbilidades, para su prevención, diagnóstico y tratamiento.
Este cambio conceptual puede influir en la calidad de vida del paciente y así predecir algún “fenotipo de paciente” quizás más predispuesto a tener una merma en su calidad de vida, pudiendo identificar factores de riesgo disponiendo de herramientas para su identificación, permitiría preverlos y actuar sobre ellos de una forma más directa y activa.
Hemos identificado factores de riesgo relacionados con la merma de calidad de vida de los pacientes con psoriasis medidos mediante un cuestionario genérico y especifico de calidad de vida , así como hemos identificado factores de riesgo relacionados con la presencia de comorbilidad psíquica ya que este factor se ha perfilado de gran importancia en la merma de calidad de vida de los pacientes con psoriasi
Urticarial lesions in a pregnant woman
No abstract available</p
Recommended from our members
Diclofenac sodium 3% gel for darier's disease treatment
Background: Darier’s disease (DD) is an autosomal dominant skin disorder which causative gene, ATP2A2, is located atchromosome 12q23–24. The lesions of DD are skin-coloured to brown, hyperkeratotic, greasy papules that coalesce into warty plaques commonly involving the seborrhoeic areas of the trunk and face, especially the scalp margins, temples, ears, and scalp. The most common complaint associated with the disease is itching, with exacerbations attributed to heat, sweating, sunlight, lithium, steroid therapy, stress, and menstruationObjectives: We report a patient with DD treated with topical diclofenac sodium 3%.Methods: We report a 33-year-old patient with Darier's Disease. He was followed in our department since 2009, and we had tried to control several flares of lesions during follow-up, but oral isotretinoin was not tolerated because of adverse effects; and oral doxycycline showed lack of efficacy.At April 2014, patient presented with new lesions, involving anterior chest wall, abdomen, back and shoulders areas. We started with diclofenac sodium 3% in hyaluronic acid 2.5% once daily, only applied at abdomen and anterior chest wall.Results: After six-month therapy, hyperkeratotic papules were flattened and less harshness of them was noticed, even some of them disappeared.Conclusions: We consider topical diclofenac therapy as a useful alternative treatment for DD patients, in which previous therapies have not shown efficacy. We did not observed topical adverse effects, neither systemic absorption symptoms, but werecognized further and larger studies are needed to asses the efficacy and safety of this treatment in DD
Recommended from our members
Diclofenac sodium 3% gel for darier's disease treatment
Background: Darier’s disease (DD) is an autosomal dominant skin disorder which causative gene, ATP2A2, is located atchromosome 12q23–24. The lesions of DD are skin-coloured to brown, hyperkeratotic, greasy papules that coalesce into warty plaques commonly involving the seborrhoeic areas of the trunk and face, especially the scalp margins, temples, ears, and scalp. The most common complaint associated with the disease is itching, with exacerbations attributed to heat, sweating, sunlight, lithium, steroid therapy, stress, and menstruationObjectives: We report a patient with DD treated with topical diclofenac sodium 3%.Methods: We report a 33-year-old patient with Darier's Disease. He was followed in our department since 2009, and we had tried to control several flares of lesions during follow-up, but oral isotretinoin was not tolerated because of adverse effects; and oral doxycycline showed lack of efficacy.At April 2014, patient presented with new lesions, involving anterior chest wall, abdomen, back and shoulders areas. We started with diclofenac sodium 3% in hyaluronic acid 2.5% once daily, only applied at abdomen and anterior chest wall.Results: After six-month therapy, hyperkeratotic papules were flattened and less harshness of them was noticed, even some of them disappeared.Conclusions: We consider topical diclofenac therapy as a useful alternative treatment for DD patients, in which previous therapies have not shown efficacy. We did not observed topical adverse effects, neither systemic absorption symptoms, but werecognized further and larger studies are needed to asses the efficacy and safety of this treatment in DD
Recommended from our members
Queratodermia plantar dolorosa y onicodistrofia en mujer joven caucásica
Pachonychia congenita is an uncommon genodermatosis, classified among the disorders of keratinization and caused by mutation of certain keratin genes. The characteristic clinical triad is onychodystrophy, keratoderma, and plantar pain. In addition, the patients may present with epidermal cysts, steatocystomas, leukokeratosis, and deciduous teeth
Recommended from our members
Queratodermia plantar dolorosa y onicodistrofia en mujer joven caucásica
Pachonychia congenita is an uncommon genodermatosis, classified among the disorders of keratinization and caused by mutation of certain keratin genes. The characteristic clinical triad is onychodystrophy, keratoderma, and plantar pain. In addition, the patients may present with epidermal cysts, steatocystomas, leukokeratosis, and deciduous teeth
Recommended from our members
Síndrome de Ross en varón de 38 años [Ross syndrome in a 38-year-old male]
Recommended from our members